Fibroblast Activation Protein—the Accomplice of Malignant Tumor

Abstract

Abstract: Fibroblast activation protein(FAP) is a kind of serine protease, mainly secreted by activated fibroblast, widely exist in epithelial tumors. The close relationship of FAP with the invasion, metastasis, angiogenesis and immune escape of tumors have been confirmed. This is a review about FAP of the structure and functions, the expression and mechanism of action in tumors, the application in diagnosis and treatment for tumors. At last, prospects for the usage of FAP in tumors.

Key words: Fibroblast activation protein, Malignant tumor, Microenvironment

Huang Tianming, Mo Farong, Luo Guorong. Fibroblast Activation Protein—the Accomplice of Malignant Tumor[J]. Biotechnology Bulletin, 2013, 0(5): 34-39.

References

[1] Klein G, Sjogren HO, Klein E, et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host[J]. Cancer Res, 1960, 20：1561-1572.
[2] Mathew S, Scanlan MJ, Mohan Raj BK, et al. The gene for fibroblast activation protein alpha(FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23[J]. Genomics, 1995, 25：335-337.
[3] Pi?eiro-Sánchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease [J]. J Biol Chem, 1997, 272(12)：7595-7601.
[4] Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth[J].Mol Cancer Ther, 2005, 4(3)：351-360.
[5] Gorrell MD, Gysbers V, McCaughan GW. CD26：a multifunctional integral membrane and secreted protein of activated lymphocy-tes[J]. Scand J Immunol, 2001, 54(3)：249-264.
[6] Kelly T. Evaluation of seprase activity[J]. Clin Exp Metastasis, 1999, 17(1)：57-62.
[7] Chen WT, Kelly T. Seprase complexes in cellular invasiveness[J].Cancer Metastasis Rev, 2003, 22(2-3)：259-269.
[8] Artym VV, Kindzelskii AL, Chen WT, et al. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes：dependence on beta1 integrins and the cytoskeleton[J]. Carcinogenesis, 2002, 23(10)：1593-1601.
[9] Mueller SC, Ghersi G, Akiyama SK, et al. A novel protease-docking function of integrin at invadopodia[J]. J Biol Chem, 1999, 274(35)：24947-24952.
[10] Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers[J]. Proc Natl Acad Sci USA, 1990, 87(18)：7235-7239.
[11] Rosenblum JS, Kozarich JW. Prolyl peptidases：a serine protease subfamily with high potential for drug discovery[J]. Curr Opin Chem Biol, 2003, 7(4)：496-504.
[12] Milner JM, Kevorkian L, Young DA, et al. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis[J].Arthritis Res Ther, 2006, 8(1)：23.
[13] Liotta LA, Kohn EC. The microenvironment of the tumour-host interface[J]. Nature, 2001, 411(6835)：375-379.
[14] Okada K, Chen WT, Iwasa S, et al. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer[J]. Oncology, 2003, 65(4)：363-370.
[15] Ariga N, Sato E, Ohuchi N, et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast[J]. Int J Cancer, 2001, 95(1)：67-72.
[16] Mikheeva SA, Mikheev AM, Petit A, et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma[J]. Mol Cancer, 2010, 9：194.
[17] Direkze NC, Hodivala-Dilke K, Jeffery R, et al. Bone marrow contr-ibution to tumor-associated myofibroblasts and fibroblasts[J].Cancer Res, 2004, 64(23)：8492-8495.
[18] Direkze NC, Jeffery R, Hodivala-Dilke K, et al. Bone marrow-derived stromal cells express lineage-related messenger RNA species[J]. Cancer Res, 2006, 66(3)：1265-1269.
[19] Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibro-blasts contribute to the mesenchymal stem cell niche and promote tumor growth[J]. Cancer Cell, 2011, 19(2)：257-272.
[20] De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth[J]. Int J Cancer, 2008, 123(10)：2229-2238.
[21] Chen H, Yang WW, Wen QT, et al. TGF-beta induces fibroblast activation protein expression；fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected][J]. Exp Mol Pathol, 2009, 87(3)：189-194.
[22] Denys H, Derycke L, Hendrix A, et al. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion[J]. Cancer Lett, 2008, 266：263-274.
[23] Zhang J, Valianou M, Cheng JD. Identification and characterization of the promoter of fibroblast activation protein[J]. Front Biosci (Elite ed), 2010, 2：1154-1163.
[24] 温秋婷, 孙玉荣, 李春红, 等.成纤维细胞激活蛋白对卵巢癌细胞增殖、迁移和侵袭的影响[J].中国癌症杂志, 2011, 21(6)：441-445.
[25] Kennedy A, Dong H, Chen D, et al. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells[J]. Int J Cancer, 2009, 124(1)：27-35.
[26] W?ster P, Rosdahl I, Gilmore BF, et al. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts：Implications for melanoma invasion[J]. Int J Oncol, 2011, 39(1)：193-202.
[27] Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex[J]. J Biol Chem, 2002, 277(32)：29231-29241.
[28] Ghersi G, Zhao Q, Salamone M, et al. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices[J]. Cancer Res, 2006, 66(9)：4652-4661.
[29] Nakahara H, Nomizu M, Akiyama SK, et al. A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides[J]. J Biol Chem, 1996, 271(44)：27221-27224.
[30] Lee HO, Mullins SR, Franco-Barraza J, et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells[J]. BMC Cancer, 2011, 11：245.
[31] Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J]. J Clin Invest, 2009, 119(12)：3613-3625.
[32] Ghilardi C, Chiorino G, Dossi R, et al. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium[J]. BMC Genomics, 2008, 9：201.
[33] Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer[J]. Cancer Res, 2004, 64(8)：2712-2716.
[34] Huang Y, Simms AE, Mazur A, et al. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions[J]. Clin Exp Metastasis, 2011, 28(6)：567-579.
[35] Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natr-iuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α[J]. FEBS J, 2011, 278(8)：1316-1332.
[36] Zukowska Z, Pons J, Lee EW, et al. Neuropeptide Y：a new mediator linking sympathetic nerves, blood vessels and immune system[J]. Can J Physiol Pharmacol, 2003, 81(2)：89-94.
[37] Dvorak HF. Tumors：wounds that do not heal. Similarities between tumor stroma generation and wound healing[J]. N Engl J Med, 1986, 315(26)：1650-1659.
[38] Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha[J]. Science, 2010, 330 (6005)：827-830.
[39] Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor imm-une microenvironment in a 4T1 murine breast cancer model[J]. PLoS One, 2009, 4(11)：e7965.
[40] Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin Invest, 2006, 116(7)：1955-1962.
[41] Adams S, Miller GT, Jesson MI, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism[J]. Cancer Res, 2004, 64 (15)：5471-5480.
[42] Narra K, Mullins SR, Lee HO, et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer[J]. Cancer Biol Ther, 2007, 6(11)：1691-1699.
[43] Eager RM, Cunningham CC, Senzer N, et al. Phase II trial of talabo-stat and docetaxel in advanced non-small cell lung cancer[J]. Clin Oncol (R Coll Radiol), 2009, 21(6)：464-472.
[44] Eager RM, Cunningham CC, Senzer NN, et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma[J]. BMC Cancer, 2009, 9：263.
[45] Kelly TA, Adams J, Bachovchin WW, et al. Immunosuppresive boronic acid dipeptides：correlation between conformation and activity[J]. J Am Chem Soc, 1993, 115(26)：12637-12638.
[46] Poplawski SE, Lai JH, Sanford DG, et al. Pro-soft Val-boroPro：a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases[J]. J Med Chem, 2011, 54(7)：2022-2028.
[47] Lai KS, Ho NH, Cheng JD, et al. Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV[J]. Bioconjug Chem, 2007, 18(4)：1246-1250.
[48] Lo PC, Chen J, Stefflova K, et al. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers[J]. J Med Chem, 2009, 52(2)：358-368.
[49] LeBeau AM, Brennen WN, Aggarwal S, et al. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin[J]. Mol Cancer Ther, 2009, 8(5)：1378-1386.
[50] Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer[J]. Clin Cancer Res, 2003, 9(5)：1639-1647.
[51] Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen tar-geting by a humanised monoclonal antibody：an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer[J]. Onkologie, 2003, 26(1)：44-48.